NLS Alligator Bioscience

Biotech company Alligator Biosciences has finished its first Phase I clinical trial with the immuno-oncology antibody ADC-1013. CDMO Cobra Biologics has manufactured the antibody as part of the company’s cell line development programme for Alligator. Cobra has developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using their maxXpress service, which harnesses the power […]

Cobra Biologics and Alligator Bioscience extend their drug development partnership. The project will deliver second cell line for manufacture of immuno-oncology antibody ADC-1015 following ADC-1013 success. Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB (Alligator), a Swedish biotechnology company. Alligator […]

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life science industry”. The 10th annual SwedenBIO Award was awarded at a price ceremony in Stockholm, Sweden, on Thursday evening. This year’s winner is Alligator Bioscience, whose pioneering research and great business acumen is a source of inspiration to companies throughout the Swedish […]

Medical device company Clinical Laserthermia Systems (CLS) has signed a collaboration agreement with Alligator Bioscience regarding future treatment strategies for tumor diseases. Both companies develop cancer therapies with immuno-modulating effects but their approaches are different. According to them these differences in approach opens up for novel possibilities and potential synergies. “The collaboration concerns early phase […]

Janssen Biotech, one of the Janssen pharmaceutical companies of Johnson & Johnson has entered an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies. Under terms of the agreement, Janssen will attain rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody. ADC-1013 targets […]

BioInvent has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum. BioInvent has manufactured ADC-1013 (a FIND optimized n-CoDeR antibody) and the company has announced that it will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to commence […]